Every 10-Q that Prothena Corporation plc (PRTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PRTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRTA filings page.
Prothena Corporation plc, a late-stage biotech focused on protein dysregulation, reported mixed results for the three and six months ended June 30, 2026. For the quarter, total revenue was $1,010 thousand and the company recorded a net loss of $18,583 thousand, or $0.36 per share, narrower than a year earlier. For the first half, total revenue rose to $52,094 thousand, including a $50,050 thousand development milestone from Novo Nordisk related to coramitug, driving net income of $14,138 thousand compared with a substantial loss in 2025.
Operating expenses fell sharply as research and development declined to $21,425 thousand for the six-month period and restructuring charges reversed to a net credit, reflecting wind-down of the birtamimab program and progress on a 2025 restructuring plan. Net cash provided by operating activities was $3,828 thousand, and cash, cash equivalents and restricted cash totaled $289,053 thousand at June 30, 2026; management believes this is sufficient to meet obligations for at least the next twelve months.
The company repurchased 2,243,888 ordinary shares for approximately $22.3 million under a $100.0 million authorization. Clinically, key partnered programs advanced, including Roche’s Phase 3 PARAISO trial of prasinezumab in early Parkinson’s disease and Novo Nordisk’s Phase 3 CLEOPATTRA trial of coramitug in ATTR cardiomyopathy, supported by earlier positive Phase 2 data and recent FDA Fast Track designations.
Prothena Corporation plc reported a profitable quarter for the period ended March 31, 2026. Total revenue rose to $51.1 million, driven mainly by a $50.0 million development milestone payment from Novo Nordisk related to coramitug, alongside $1.0 million of collaboration revenue from Bristol Myers Squibb.
The company generated net income of $32.7 million, or $0.60 per diluted share, compared with a net loss of $60.2 million a year earlier. Research and development expense fell to $12.6 million from $50.8 million, reflecting lower spend after discontinuing birtamimab and the impact of a $4.2 million net reduction in restructuring costs.
Cash and cash equivalents were $329.5 million, and management believes this balance will fund operations for at least 12 months. Prothena repurchased 788,990 ordinary shares for about $7.3 million and ended the quarter with 53.1 million shares outstanding and shareholders’ equity of $312.6 million, while continuing to advance late-stage programs with Roche, Novo Nordisk and Bristol Myers Squibb.
Prothena (PRTA) reported Q3 2025 results showing modest collaboration revenue and lower operating spend amid an ongoing restructuring. Total revenue was $2.4 million for the quarter and $9.7 million year-to-date. Research and development expense declined to $28.9 million in Q3, with program spend led by PRX012 ($14.7 million), followed by birtamimab ($7.1 million) and PRX019 ($2.2 million). General and administrative expense was $13.2 million in Q3; restructuring costs totaled $33.1 million year-to-date.
The company recorded a Q3 net loss of $36.5 million and a year-to-date net loss of $222.5 million. Cash and cash equivalents were $330.8 million as of September 30, 2025, compared with $471.4 million at year-end 2024, reflecting $140.3 million used in operating activities year-to-date. Shareholders’ equity was $295.0 million, with total assets of $352.6 million.
Prothena’s collaboration with BMS continues to contribute deferred revenue tied to the PRX019 Phase 1 clinical trial obligation, with $2.4 million recognized in Q3 and $2.7 million remaining as of quarter end. Ordinary shares outstanding were 53,829,982 as of October 31, 2025.